Search clinical trials for: BGB-A333

Total 1363 results

BeiGene

Completed

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

Limited Stage Small Cell Lung Cancer

China, Korea, Republic of, United States
BeiGene

Completed

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

Covid19

United States, Mexico, Brazil, South Africa
Amgen

Terminated

Phase I, Double-Blind,Placebo, MAD Study to Evaluate the Safety, Tolerability, PK, and PD of AMG 333 in Healthy Subjects and Migraine Subjects

Migraine

United States
Amgen

Completed

Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines

Migraine

United States
BeiGene

Completed

Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China

HER2-negative Breast Cancer

China
BeiGene

Completed

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants

Covid19

Australia
BeiGene

Recruiting

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Follicular Lymphoma | Waldenström Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | B-cell Malignancy | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Richter's Transformation | DLBCL Unclassifiable

China
Peter MacCallum Cancer Centre, Australia

Completed

MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial (MYPHISMO)

Adenoid Cystic Carcinoma | Colorectal Cancer

Australia
BeiGene

Recruiting

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Advanced Solid Tumor | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma

China, Australia
Chong Kun Dang Pharmaceutical

Completed

Pharmacokinetics and Safety Profile of CKD-333

Hypertension | Dyslipidemias

Korea, Republic of
BeiGene

Completed

AdvanTIG-203: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

Korea, Republic of, Spain, China, Thailand, Taiwan, France
Kowa Company, Ltd.

Completed

Study of Peretinoin for Suppressing Recurrence of HCV-positive HCC

Hepatic Neoplasm Malignant Recurrent

Japan
BeiGene

Completed

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 in Healthy Males

Healthy Volunteers

United States
BeiGene

Recruiting

Study to Evaluate the Efficacy and Safety of BGB-11417 in Participants With Waldenström's Macroglobulinemia

Waldenstrom Macroglobulinemia | Waldenstrom's Macroglobulinemia Recurrent | Waldenstrom's Macroglobulinemia Refractory

United States, Australia, France, China, Spain, United Kingdom
BeiGene

Completed

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

Lymphoma | Leukemia

China, Australia
BeiGene

Recruiting

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Follicular Lymphoma | Waldenström Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | B-cell Malignancy

United States, Spain, Italy, Australia, France, Korea, Republic of, United Kingdom, Canada, Brazil, Georgia, Sweden, Germany, Moldova, Republic of
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI); BeiGene

Completed

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | IDH1 Mutation | IDH2 Mutation

United States
German CLL Study Group

Active, not recruiting

Efficacy and Safety of Zanubrutinib Plus Tislelizumab for Treatment of Patients With Richter Transformation (CLL-RT1)

Richter Transformation

Denmark, Germany, Austria
Sun Yat-sen University

Recruiting

Pamiparib in mCRPC With HRD or BRCA1/2 Mutation

Metastatic Castration-resistant Prostate Cancer

China
BeiGene

Recruiting

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB A1217) in Combination With Tislelizumab (BGB A317) or Rituximab

Relapsed Diffuse Large B-cell Lymphoma | Refractory Diffuse Large B-cell Lymphoma

China
BeiGene

Recruiting

Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

China, Georgia, Moldova, Republic of
Qilu Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer

Lung Cancer
BeiGene USA, Inc.

Completed

A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma

Brain and Central Nervous System Tumors

United States, Netherlands, Switzerland
M.D. Anderson Cancer Center

Recruiting

Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm

United States
AbbVie (prior sponsor, Abbott)

Completed

A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies

HCV Infection

United States, Puerto Rico
University of California, San Francisco
National Cancer Institute (NCI); National Institutes of Health (NIH)

Not yet recruiting

IMProving Adherence to Colonoscopy Through Teams and Technology (IMPACTT)

Colorectal Cancer | Colon Cancer | Cancer Colorectal

United States
BeiGene

Active, not recruiting

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

NSCLC | Non-small Cell Lung Cancer

United States
Pfizer

Completed

Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease

Alzheimer Disease

Australia, France, Spain, United States, South Africa, Italy, Argentina, Poland, Finland, United Kingdom, Canada
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma
Tongji Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Combination of ETV, TQ-A3334 and TQ-B2450 for CHB (Neptune Study) (Neptune)

Chronic Hepatitis b
Qilu Hospital of Shandong University

Not yet recruiting

First-line Treatment With RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer (RCTS)

HER2-positive Gastric Cancer

China
Bausch Health Americas, Inc.

Completed

Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC) (OIC)

Constipation

United States
BeiGene

Recruiting

Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies

B-cell Malignancies

China, Italy, United States, Spain, United Kingdom, Poland, Czechia, Netherlands, Greece, France, Sweden, Korea, Republic of, Turkey
Intra-Cellular Therapies, Inc.
National Institute on Drug Abuse (NIDA)

Recruiting

A PET Study Following a Single Oral Dose of ITI-333 in Healthy Subjects

Healthy Volunteers

United States
Kymera Therapeutics, Inc.

Recruiting

Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors

Solid Tumors | T-cell Prolymphocytic Leukemia (T-PLL) | Non Hodgkin Lymphoma (NHL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-Cell Lymphoma (CTCL) | Large Granular Lymphocytic Leukemia (LGL-L)

United States
Seoul National University Hospital

Terminated

Phase 1 and Phase 2 Clinical Trials of SNUBH-NM-333(18F)

Alzheimer Disease

Korea, Republic of
Hospital Severo Ochoa
Instituto de Salud Carlos III

Completed

Usefulness and Safeness Of Intra-Gastric Balloon Before Bariatric Surgery In Morbid Obesity

Morbid Obesity

Spain
BeiGene

Not yet recruiting

Phase 1 First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Advanced Solid Tumor
BeiGene

Active, not recruiting

Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Patients With Colorectal Cancer

Colorectal Cancer

China
BeiGene

Completed

Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody

Advanced Solid Tumors

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets

Non-small Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients

MCL
Zhongda Hospital

Recruiting

Tislelizumab in Combination With TACE in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
BeiGene

Active, not recruiting

Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma

Resectable Esophageal Squamous Cell Carcinoma

China
BeiGene
Lymphoma Study Association

Active, not recruiting

Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (TIRHOL)

Classical Hodgkin Lymphoma

United States, Australia, France, Belgium, Puerto Rico
Cancer Institute and Hospital, Chinese Academy...

Active, not recruiting

Tislelizumab Combined With Chemotherapy in First-line Treatment of AGC

Chemotherapy | Gastric Cancer Stage IV | Tislelizumab | First-line

China
Celgene
BeiGene

Terminated

A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer (RATIONALE001)

Carcinoma, Non-Small-Cell Lung

Spain, United States, Japan, China, Canada, United Kingdom, Belgium, Singapore, Korea, Republic of, Netherlands, France, Romania, Greece, Germany, Taiwan, Finland, Italy, Poland, Hungary, Ireland, Portugal, New Zealand, Russian Federation
BeiGene

Not yet recruiting

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Advanced or Metastatic Solid Tumors

Metastatic Solid Tumor | Advanced Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | Alpha-fetoprotein (AFP)-Producing Gastric Cancer | Extragonadal Yolk Sac Tumors | Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer
BeiGene

Completed

AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer

Cervical Cancer

Korea, Republic of, Taiwan, China, Thailand, Poland, Bulgaria, Russian Federation, Ukraine
Intra-Cellular Therapies, Inc.
National Institute on Drug Abuse (NIDA)

Recruiting

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers

Healthy Volunteers

United States

Search clinical trials for: BGB-A333

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations